Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD

• Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency
• Lack of impact of belapectin on cardiac repolarization (QT interval)
• Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertension and liver cirrhosis
• Clinical significance and interpretation of serum galectin-3 levels in patients with advanced liver disease
• Impact of obesity and muscle wasting to evaluate renal function in patients with portal hypertension and NASH cirrhosis
  

NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting will be held November 10-14, 2023, in Boston, Mass.

“This year again we are happy to share some of the progress we have made in our global program with belapectin, our galectin-3 inhibitor. We are also proud to bring additional knowledge to the field regarding liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long,” said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics. “In liver cirrhosis, the early recognition of portal hypertension is essential to address the cirrhotic disease process at a stage when it is still potentially reversible, before the time liver transplant becomes the only curative option. We will share more information on the safety profile of belapectin and the fact that its pharmacokinetics properties are not affected by the degree of liver impairment.”

Dr. Boudes continued: “Contrary to most drugs that need to be metabolized by hepatocytes, we think that the unique and advantageous characteristics of belapectin are explained by its carbohydrate composition and its preferential distribution to intra-hepatic activated macrophages, the very cells that produce galectin-3. We link these characteristics to the apparent good tolerance and safety profile of belapectin highlighted during the recent, fourth independent Data and Safety Monitoring Board review of our global pivotal study NAVIGATE.”